General Information of the Drug (ID: M6APDG02328)
Name
2,6-dihydroxy-1,7-dimethoxyxanthone
Synonyms
calophymembranol A; 2,6-dihydroxy-1,7-dimethoxyxanthone; CHEMBL463769; AC1NRZXJ; BDBM50269644; 2,6-dihydroxy-1,7-dimethoxyxanthen-9-one
    Click to Show/Hide
Status
Investigative
Structure
Formula
C15H12O6
InChI
1S/C15H12O6/c1-19-12-5-7-11(6-9(12)17)21-10-4-3-8(16)15(20-2)13(10)14(7)18/h3-6,16-17H,1-2H3
InChIKey
SROSPGQNFCAFNO-UHFFFAOYSA-N
PubChem CID
5326145
TTD Drug ID
D0S7LD
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Prostaglandin G/H synthase 2 (COX-2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2,6-dihydroxy-1,7-dimethoxyxanthone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2,6-dihydroxy-1,7-dimethoxyxanthone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). [1], [2]
References
Ref 1 METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte. Biochem Biophys Res Commun. 2019 Aug 13;516(1):22-27. doi: 10.1016/j.bbrc.2019.05.168. Epub 2019 Jun 8.
Ref 2 Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum. J Nat Prod. 2005 Oct;68(10):1514-8. doi: 10.1021/np0502342.